Should I buy or sell 10x Genomics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares. View TXG analyst ratings or view top-rated stocks .

What is 10x Genomics' stock price target for 2024?

8 analysts have issued 12 month target prices for 10x Genomics' stock. Their TXG share price targets range from $47.00 to $75.00. On average, they expect the company's share price to reach $60.78 in the next year. This suggests a possible upside of 34.1% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts .

How have TXG shares performed in 2023?

10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG shares have increased by 24.4% and is now trading at $45.33. View the best growth stocks for 2023 here .

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our TXG earnings forecast .

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) announced its earnings results on Thursday, November, 2nd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.06. The company had revenue of $153.64 million for the quarter, compared to analyst estimates of $150.11 million. 10x Genomics had a negative trailing twelve-month return on equity of 24.24% and a negative net margin of 37.79%.

What ETFs hold 10x Genomics' stock?

ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , Fidelity Disruptive Medicine ETF (FMED) , ARK Genomic Revolution ETF (ARKG) , ARK Innovation ETF (ARKK) , BNY Mellon Innovators ETF (BKIV) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC) .

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com . Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.72%), Baillie Gifford & Co. (7.06%), Morgan Stanley (3.68%), Sands Capital Management LLC (3.37%), ARK Investment Management LLC (2.55%) and Invesco Ltd. (1.88%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson , Bradford Crutchfield , James Wilbur , John R Stuelpnagel, John R Stuelpnagel , Justin J Mcanear, Justin J Mcanear , Mathai Mammen , Serge Saxonov and Sridhar Kosaraju . View institutional ownership trends .

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

10x Genomics Stock Price, News & Analysis (NASDAQ:TXG)

$45.33

-0.96 (-2.07%)

(As of 12/5/2023 ET)

Compare

Today's Range: $44.57
▼
$46.04
50-Day Range: $34.32
▼
$46.29
52-Week Range: $31.28
▼
$63.57

Volume: 748,925 shs
Average Volume: 964,386 shs
Market Capitalization: $5.36 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $60.78

10x Genomics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 34.1% Upside
$60.78 Price Target
Short Interest: Healthy
4.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.73
Upright™ Environmental Score
News Sentiment: 0.34
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.84) to ($1.48) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

143rd out of 948 stocks

Analytical Instruments Industry

7th out of 27 stocks

3.4

Analyst's Opinion

Consensus Rating
10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $60.78, 10x Genomics has a forecasted upside of 34.1% from its current price of $45.33.
Amount of Analyst Coverage
10x Genomics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.81% of the outstanding shares of 10x Genomics have been sold short.
Short Interest Ratio / Days to Cover
10x Genomics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in 10x Genomics has recently decreased by 15.73%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
10x Genomics does not currently pay a dividend.
Dividend Growth
10x Genomics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.
Environmental Sustainability
The Environmental Impact score for 10x Genomics is -0.73.

1.9

News and Social Media Coverage

News Sentiment
10x Genomics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for 10x Genomics this week, compared to 3 articles on an average week.
Search Interest
Only 2 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
5 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,267,546.00 in company stock.
Percentage Held by Insiders
10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.16% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for 10x Genomics are expected to grow in the coming year, from ($1.84) to ($1.48) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of 10x Genomics is -23.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of 10x Genomics is -23.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
10x Genomics has a P/B Ratio of 6.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TXG Stock News Headlines

December 4, 2023 | reuters.com

10x Genomics sues rival Curio over gene-sequencing technology

November 29, 2023 | tmcnet.com

BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer

December 5, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 28, 2023 | americanbankingnews.com

10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $72,767.86 in Stock

November 28, 2023 | americanbankingnews.com

Insider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 3,757 Shares of Stock

November 28, 2023 | americanbankingnews.com

Serge Saxonov Sells 3,723 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

November 28, 2023 | americanbankingnews.com

Insider Selling: 10x Genomics, Inc. (NASDAQ:TXG) Insider Sells 3,464 Shares of Stock

November 27, 2023 | msn.com

JP Morgan downgrades NanoString to neutral over patent litigation

December 5, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 27, 2023 | americanbankingnews.com

10x Genomics, Inc. (NASDAQ:TXG) Receives Average Rating of "Moderate Buy" from Analysts

November 25, 2023 | americanbankingnews.com

Reviewing 10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY)

November 23, 2023 | benzinga.com

Chief Commercial Officer of 10x Genomics Sold $619K In Stock

November 23, 2023 | finance.yahoo.com

Insider Sell Alert: Chief Commercial Officer James Wilbur Sells Shares of 10x Genomics Inc

November 20, 2023 | msn.com

NanoString falls as company pulls guidance after patent setback

November 20, 2023 | benzinga.com

Why Is Life Science Company NanoString Stock Trading Lower Today?

November 19, 2023 | finance.yahoo.com

Harvard University Stocks List: Top 12 Picks

November 17, 2023 | finance.yahoo.com

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

November 9, 2023 | finance.yahoo.com

Here’s Why You Should Invest in 10x Genomics (TXG)

November 4, 2023 | markets.businessinsider.com

Sell Rating on 10x Genomics: Analysis of Q3 Performance and Future Growth Concerns

November 4, 2023 | seekingalpha.com

10x Genomics: Unveiling The Investment Potential

November 3, 2023 | markets.businessinsider.com

10x Genomics Outperforms Expectations: Xenium Segment Fuels Growth Amid Revised Revenue Guidance

November 3, 2023 | finance.yahoo.com

Q3 2023 10X Genomics Inc Earnings Call

November 3, 2023 | finance.yahoo.com

10x Genomics, Inc. (NASDAQ:TXG) Q3 2023 Earnings Call Transcript

November 3, 2023 | msn.com

10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

November 2, 2023 | finance.yahoo.com

10x Genomics Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

10x Genomics Inc (TXG) Reports 17% Revenue Increase in Q3 2023

November 1, 2023 | finance.yahoo.com

10x Genomics to Present at the Stephens 25th Annual Conference

See More Headlines

Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TXG
CUSIP: N/A
CIK: 1770787
Web: www.10xgenomics.com
Phone: 925-401-7300
Fax: N/A
Employees: 1,243
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.78
High Stock Price Target: $75.00
Low Stock Price Target: $47.00
Potential Upside/Downside: +34.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-166,000,000.00
Net Margins: -37.79%
Pretax Margin: -36.99%
Return on Equity: -24.24%
Return on Assets: -19.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.37
Quick Ratio: 4.60

Sales & Book Value

Annual Sales: $516.41 million
Price / Sales: 10.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.99 per share
Price / Book: 6.48

Miscellaneous

Outstanding Shares: 118,210,000
Free Float: 105,620,000
Market Cap: $5.36 billion
Optionable: Optionable
Beta: 1.88

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Serge Saxonov Ph.D. (Age 46)
Co-Founder, CEO & Director
Comp: $837.68k
Dr. Benjamin J. Hindson Ph.D. (Age 48)
Co-Founder, President, Chief Scientific Officer & Director
Comp: $615.96k
Mr. Justin J. McAnear (Age 47)
Chief Financial Officer
Comp: $535.91k
Mr. Eric S. Whitaker Esq. (Age 56)
Chief Legal Officer
Comp: $558.97k
Mr. James L. Wilbur Ph.D. (Age 58)
Chief Commercial Officer
Comp: $390.78k
Mr. Michael Schnall-Levin
Founding Scientist & CTO
Ms. Cassie Corneau
Manager of Investor Relations and Strategic Finance
Ms. Rebecca Port
Chief People Officer
Mr. James Bryant
Director of Legal
Mr. Nikhil Rao
Director of Product Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings or view top-rated stocks.
What is 10x Genomics' stock price target for 2024?: 8 analysts have issued 12 month target prices for 10x Genomics' stock. Their TXG share price targets range from $47.00 to $75.00. On average, they expect the company's share price to reach $60.78 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts price targets for TXG or view top-rated stocks among Wall Street analysts.
How have TXG shares performed in 2023?: 10x Genomics' stock was trading at $36.44 at the start of the year. Since then, TXG shares have increased by 24.4% and is now trading at $45.33.
View the best growth stocks for 2023 here.
When is 10x Genomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our TXG earnings forecast.
How were 10x Genomics' earnings last quarter?: 10x Genomics, Inc. (NASDAQ:TXG) announced its earnings results on Thursday, November, 2nd. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.06. The company had revenue of $153.64 million for the quarter, compared to analyst estimates of $150.11 million. 10x Genomics had a negative trailing twelve-month return on equity of 24.24% and a negative net margin of 37.79%.
What ETFs hold 10x Genomics' stock?: ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Disruptive Medicine ETF (FMED), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), BNY Mellon Innovators ETF (BKIV), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC).

What is Serge Saxonov's approval rating as 10x Genomics' CEO?: 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did 10x Genomics IPO?: (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.
Who are 10x Genomics' major shareholders?: 10x Genomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.72%), Baillie Gifford & Co. (7.06%), Morgan Stanley (3.68%), Sands Capital Management LLC (3.37%), ARK Investment Management LLC (2.55%) and Invesco Ltd. (1.88%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends.
How do I buy shares of 10x Genomics?: Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

10x Genomics Stock Price, News & Analysis (NASDAQ:TXG)

10x Genomics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About 10x Genomics Stock (NASDAQ:TXG)

TXG Stock Price History

TXG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TXG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™